China grants country's first Covid-19 vaccine patent to CanSino

CanSino Biologics won approval last week for its Covid-19 vaccine candidate Ad5-nCOV, state media reports; phase 3 trials to be conducted in Saudi Arabia and several other countries

by Reuters
China grants country's first Covid-19 vaccine patent to CanSino
Chinese vaccine maker CanSino Biologics' sign is pictured on its building in Tianjin, China on November 20, 2018. Photo: Reuters /Stringer.

China's vaccine specialist CanSino Biologics Inc has won a patent approval from Beijing for its Covid-19 vaccine candidate Ad5-nCOV, state media reported, citing documents from the country's intellectual property regulator.

It is the first Covid-19 vaccine patent granted by China, state-owned newspaper People's Daily reported on Sunday.

The paper cited documents published by China's National Intellectual Property Administration saying that the patent was issued on August 11.

Saudi Arabia said this month it plans to begin Phase III clinical trials for the CanSino vaccine. CanSino has said it is also in talks with Russia, Brazil and Chile to launch Phase III trials in those countries.

CanSino's Hong Kong shares rose around 14% in Monday's morning session. Its Shanghai shares rose by 6.6% as of midday.